Loading clinical trials...
Loading clinical trials...
Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan
Conditions
Interventions
Recombinant human interferon α1β
Start Date
March 1, 2020
Primary Completion Date
May 30, 2020
Completion Date
June 30, 2020
Last Updated
March 3, 2020
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
Tongji Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions